Meningococcal Vaccine Market Size, Share, and Trends 2024 to 2033

Meningococcal Vaccine Market Size and Growth

The global meningococcal vaccine market size was USD 3.54 billion in 2023, calculated at USD 3.75 billion in 2024 and is expected to reach around USD 6.36 billion by 2033, expanding at a CAGR of 6.03% from 2024 to 2033.

Meningococcal Vaccine Trials Market Key Takeaways

• North America dominated the global meningococcal vaccine market in 2023.
• By type, the conjugate vaccines segment accounted for the dominating share of the market in 2023.
• By type, the polysaccharide vaccines segment is expected to witness considerable growth in the global market over the forecast period.
• By end-user, the adult segment held the largest share of the market in 2023.
• By end-user, the children segment is expected to grow significantly in the market during the forecast period.

U.S. Meningococcal Vaccine Market Size and Growth 2024 to 2033

The U.S. meningococcal vaccine market size was exhibited at USD 1.54 billion in 2023 and is projected to be worth around USD 2.81 billion by 2033, poised to grow at a CAGR of 6.19% from 2024 to 2033.

North America dominated the global meningococcal vaccine market in 2023. The region’s growth is driven by the presence of sophisticated healthcare infrastructure, increasing prevalence of meningococcal diseases, access to effective treatment, and rise in government awareness campaigns to educate regarding the risks involved in meningitis and its required preventive measures. Moreover, supportive government policies and rising research activities focused on vaccine development are some of the prime factors expected to drive the growth of the North American market.

Among all countries, the United States is the largest meningococcal vaccine market owing to the well-developed healthcare infrastructure, rise in healthcare expenditure, presence of major pharmaceutical companies, rise in the incidence of meningitis, and favorable government initiatives for disease prevention. As a result, the demand for meningococcal vaccines has significantly increased, and timely vaccination is being carried out in the United States. Furthermore, prominent market players are investing highly in the development of an effective meningococcal vaccine in the region.

The incidence of meningococcal disease is rising in the United States. According to the CDC report in April 2024, as of March 25, 143 cases of meningococcal disease have been reported in the United States, compared with 81 for the same period in 2023. For all of 2023, 422 cases were reported, the highest annual figure since 2014.

• In March 2024, The American Society for Meningitis Prevention (ASMP) launched to empower Americans to take action to prevent meningococcal meningitis, a life-threatening bacterial infection. Founded by Patti Wukovits and Alicia Stillman, two mothers who tragically lost their daughters to meningococcal meningitis, ASMP aims to raise awareness among adolescents, young adults, parents, healthcare providers, and policymakers about meningococcal meningitis and the critical role of comprehensive vaccination in preventing it.

Europe is anticipated to grow at a notable growth rate in the meningococcal vaccine market during the forecast period. The fastest growth of the region is attributed to the increasing cases of meningitis, improving access to healthcare systems, supportive government initiatives to combat the rising prevalence of the disease, and increasing new research and development activities. Additionally, rising awareness of meningococcal disease and the significance of timely vaccination are expected to contribute to the growth of the region. Partnership and collaboration among key market players in the region are expected to propel the growth of the meningococcal vaccine market.

• In July 2022, Abacus Diagnostics announced the launch of a new rapid PCR test in the European markets for the fast identification of viruses causing viral meningitis and encephalitis. Neisseria meningitidis, or meningococcus, is a bacterium that can cause meningitis and other forms of meningococcal disease.
• In May 2024, according to the European Centre for Disease Prevention and Control, ECDC is monitoring reports from 3 countries (France, the United Kingdom, and the United States) of cases of invasive meningococcal disease (IMD) associated with travel to the Kingdom of Saudi Arabia (KSA).

Market Overview

Meningococcal disease is a rare, life-threatening, and serious disease. This disease is caused by a bacteria known as Neisseria meningitidis. It is an infection of the brain and spinal cord and can cause blood infections, too. Meningococcal vaccines play an effective role in protecting the body against infection from Neisseria meningitidis bacteria that cause meningococcal disease. By vaccination, an individual can fight against meningococcal infection. Meningococcal vaccines help to reduce the prevalence of meningitis outbreaks as well as protect and save valuable lives.

Meningococcal Vaccine Trials Market Growth Factors

• In the meningococcal vaccine market, the rising susceptibility of the vulnerable population group to bacterial attack is a major growth factor.
• State and federal support in the forms of grants and investments helps research and developmental activities in the meningococcal vaccine market.
• Rising awareness about the condition and increasing healthcare expenditure drives the growth of the meningococcal vaccine market.

Meningococcal Vaccine Market Scope

Meningococcal Vaccine Trials Market Dynamics

Driver

Increasing prevalence of meningitis

The increasing prevalence of meningitis across the globe is expected to boost the growth of the meningococcal vaccine market. Meningococcal disease is a serious health condition that requires immediate treatment as it affects the thin layers of tissue that cover and protect the brain and spinal cord. The proper vaccination against meningococcal infection helps prevent meningococcal disease, which is caused by Neisseria meningitidis bacterium.

Vaccines target specific serogroups of meningococcal bacteria, such as serogroups A, B, C, W, and Y, which cause meningococcal disease. Meningococcal vaccines are widely used to immunize children and infants against Neisseria meningitides bacteria. Therefore, increasing cases of meningococcal disease are expected to spur the demand for meningococcal vaccine market during the forecast period.

Restraint

High cost

The high cost associated with meningococcal vaccines is projected to hamper the market's growth. It can be a financial burden for an individual to purchase this vaccine. High costs may discourage poor people from seeking vaccinations. In addition, the lack of adequate healthcare infrastructure in lower-income countries may limit the adoption and restrict the expansion of the global meningococcal vaccine market during the forecast period.

Opportunity

Rising awareness programs

The increasing awareness programs regarding timely vaccination to fight against meningococcal disease, coupled with supportive government and NGO incentives, are projected to create a significant growth opportunity for the meningococcal vaccine market. Several campaigns and awareness programs, such as the Meningitis Research Foundation of Canada, the National Meningitis Association (NMA), the Meningitis B Action Project, and other awareness programs. Such awareness programs assist in fueling continuous research and innovative approaches for the prevention of meningococcal disease. Thereby driving the expansion of the meningococcal vaccine market.

Type Insights

The conjugate vaccines segment accounted for the dominating share of the meningococcal vaccine market in 2023 owing to its high efficacy and immunization to fight against meningococcal disease. Conjugate meningococcal vaccine protects against meningococcal group A and C disease. These vaccines are recommended by healthcare professionals, particularly for infants and adolescents.

The polysaccharide vaccines segment is expected to witness considerable growth in the global meningococcal vaccine market over the forecast period. Meningococcal polysaccharide vaccine protects from bacterial meningitis. This vaccine is recommended by healthcare professionals for certain risk groups to control the meningococcal epidemic, and it is available in different forms, such as bivalent, trivalent, and tetravalent. Thereby driving the segment's growth.

End-user Insights

The adult segment held the largest share of the meningococcal vaccine market in 2023. The growth of the segment is driven by increasing cases of meningococcal disease in adults. Adults who travel to areas with a high incidence of the disease are at higher risk of contracting the disease.

The children segment is expected to grow significantly in the meningococcal vaccine market during the forecast period owing to the rising awareness campaign by the government and NGOs about meningococcal disease coupled with increasing emphasis on vaccination as an effective and preventive measure. Routine vaccination is recommended for infants with meningococcal disease. Additionally, the ongoing clinical trials to develop novel vaccines for children are expected to fuel the segment’s expansion.

Meningococcal Vaccine Market Companies

• AstraZeneca plc
• Pfizer Inc.
• Novartis AG
• Janssen Pharmaceuticals, Inc.
• Bharat Biotech International Ltd.
• Mitsubishi Tanabe Pharma Corporation
• GlaxoSmithKline plc
• Sanofi Pasteur
• Merck & Co., Inc.
• Serum Institute of India Pvt. Ltd.
• Biomed Pvt. Ltd.
• Walvax Biotechnology Co., Ltd.
• Bavarian Nordic A/S
• Biological E Limited
• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corporation Limited
• Chongqing Zhifei Biological Products Co., Ltd.
• GSK Biologicals SA
• Incepta Pharmaceuticals Ltd.
• Panacea Biotec Ltd.

Recent Developments

• In April 2024, Nigeria announced the launch of the new Men5CV vaccine, which offers protection against five strains of the Neisseria meningitidis bacteria (meningococcus) responsible for meningitis. Nigeria becomes the first country globally to launch the vaccine, which is recommended by the World Health Organization (WHO).
• In October 2023, Pfizer Inc. announced that the U.S. FDA had approved PENBRAYA (meningococcal groups A, B, C, W, and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
• In July 2023, the Serum Institute of India’s (SII) multivalent meningococcal meningitis vaccine received World Health Organisation (WHO) prequalification. MenFive is the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa.

Segments Covered in the Report

By Type

• Polysaccharide Vaccines
• Conjugate Vaccines
• Combination Vaccines
• Other Types

By End-user

• Children
• Adults

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa